Citation

BibTex format

@article{Lee:2026:10.1016/j.ejca.2026.116749,
author = {Lee, P-C and Cortellini, A and Stefanini, B and Yoo, C and Chon, HJ and Cheon, J and Kudo, M and Nishida, N and Scheiner, B and Pinter, M and Lombardi, P and Fulgenzi, CAM and D'Alessio, A and Brunetti, L and Torkpour, A and Valenzi, E and Crowley, F and Marron, TU and Hsu, W-F and Celsa, C and Cabibbo, G and Camm脿, C and Galle, PR and Vivaldi, C and Masi, G and Sharma, R and Lin, RP-T and Lin, C-Y and Wietharn, B and Saeed, A and Tovoli, F and Piscaglia, F and Dalbeni, A and Auriemma, A and Sacerdoti, D and Parisi, A and Manfredi, GF and Dondo, A and Rimassa, L and Pirisi, M and Sch枚nlein, M and von, Felden J and Singal, AG and Parkih, ND and Andanamala, H and Ulahannan, S and Roehlen, N and Thimme, R and Huang, Y-H and Pinato, DJ},
doi = {10.1016/j.ejca.2026.116749},
journal = {Eur J Cancer},
title = {Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.},
url = {http://dx.doi.org/10.1016/j.ejca.2026.116749},
volume = {240},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Despite the proven superiority against sorafenib, atezolizumab plus bevacizumab (A+B) lacks long-term efficacy data in unresectable hepatocellular carcinoma (uHCC). This study assessed clinicopathologic factors associated with long-term survival with A+B. METHODS: We analyzed patients receiving first-line A+B within AB-Real, a large multicenter registry across Europe, Asia, and the USA. Long-term survivors (LTS) were defined as patients surviving at 24 months. Landmark survival outcomes and associations between baseline clinicopathologic factors and overall survival (OS) were evaluated. RESULTS: Of 1346 patients enrolled, 1085 with Child-Pugh A and ECOG 0-1 received first-line A+B. The median OS was 19.2 months (95% CI: 17.6-20.9), and 2- and 3-year survival rates were 41.4% and 29.3%. Among 695 patients with adequate follow-up, 190 were classified as LTS. The overall response rate was 24.7%, and long-term survivorship was significantly enhanced in radiologic responders (52.2% vs 8.8%, p<0.001). Compared to non-LTS, LTS more frequently had ALBI grade 1 liver reserve (64.6% vs 38.5%), less PVI (17.9% vs 36.4%), smaller maximum tumor size (3.8 vs 7.0cm), and lower AFP (median 23.0 vs 240.8 ng/mL) (all p<0.001). Notably, nearly half (48.8%) of radiologic responders who did not achieve long-term survival had ≥2 adverse baseline features, underscoring that tumor burden and liver reserve remain prognostically relevant even among responders. CONCLUSIONS: AB-Real provides the first global real-world evidence of long-term efficacy of A+B in uHCC. Long-term survivorship is enhanced in radiological responders and strongly associated with pre-treatment tumor factors and liver function.
AU  - Lee,P-C
AU  - Cortellini,A
AU  - Stefanini,B
AU  - Yoo,C
AU  - Chon,HJ
AU  - Cheon,J
AU  - Kudo,M
AU  - Nishida,N
AU  - Scheiner,B
AU  - Pinter,M
AU  - Lombardi,P
AU  - Fulgenzi,CAM
AU  - D'Alessio,A
AU  - Brunetti,L
AU  - Torkpour,A
AU  - Valenzi,E
AU  - Crowley,F
AU  - Marron,TU
AU  - Hsu,W-F
AU  - Celsa,C
AU  - Cabibbo,G
AU  - Camm脿,C
AU  - Galle,PR
AU  - Vivaldi,C
AU  - Masi,G
AU  - Sharma,R
AU  - Lin,RP-T
AU  - Lin,C-Y
AU  - Wietharn,B
AU  - Saeed,A
AU  - Tovoli,F
AU  - Piscaglia,F
AU  - Dalbeni,A
AU  - Auriemma,A
AU  - Sacerdoti,D
AU  - Parisi,A
AU  - Manfredi,GF
AU  - Dondo,A
AU  - Rimassa,L
AU  - Pirisi,M
AU  - Sch枚nlein,M
AU  - von,Felden J
AU  - Singal,AG
AU  - Parkih,ND
AU  - Andanamala,H
AU  - Ulahannan,S
AU  - Roehlen,N
AU  - Thimme,R
AU  - Huang,Y-H
AU  - Pinato,DJ
DO  - 10.1016/j.ejca.2026.116749
PY  - 2026///
TI  - Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
T2  - Eur J Cancer
UR  - http://dx.doi.org/10.1016/j.ejca.2026.116749
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42030777
VL  - 240
ER  -
Download